Kenneth Sokolski
Psychiatry · Huntington Beach, CANPI 1841395530
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 931 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 931 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Ironshore Pharmaceuticals Inc.$1K
- Tris Pharma Inc$1K
- Otsuka America Pharmaceutical, Inc.$991
- Takeda Pharmaceuticals U.S.A., Inc.$971
- plus $10K from 27 others
What the payments were for
- Food & beverage$19,224100%
- Education$930%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$449
- VRAYLAR$372
- XYREM$239
- Jornay PM 20mg capsules (Bottle of 100)$149
- CAPLYTA$129
- REXULTI$124
- SPRAVATO$118
- ARISTADA INITIO$112
How this compares
$19,317 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $169,870 |
| RexultiBrexpiprazole | 81 | $126,231 |
| AuvelityDextromethorphan Hbr/Bupropion | 59 | $66,030 |
| VraylarCariprazine Hcl | 27 | $49,243 |
| Invega SustennaPaliperidone Palmitate | 12 | $28,661 |
| CaplytaLumateperone Tosylate | 12 | $19,850 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $16,884 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $9,741 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 220 | $7,267 |
| Lisdexamfetamine Dimesylate | 34 | $7,154 |
| Lurasidone Hcl | 96 | $5,842 |
| ConcertaMethylphenidate Hcl | 11 | $5,080 |
| Bupropion XlBupropion Hcl | 220 | $4,722 |
| Aripiprazole | 56 | $2,742 |
| Paliperidone ErPaliperidone | 12 | $2,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $78 | $169,87022 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $991 | $126,23181 claims |
| Axsome Therapeutics, Inc.Auvelity | $513 | $66,03059 claims |
| AbbVieVraylar | $3,170 | $49,24327 claims |
| Johnson & JohnsonInvega Sustenna, Concerta | $365 | $33,74123 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,337 | $19,85012 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $22 | $16,88412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $971 | $9,74122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Huntington Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.